Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
| العنوان: | Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer |
|---|---|
| المؤلفون: | Shuchie Jaggi, Imali Sirisena, Pankaj Sharda, James Luke Godwin, Colleen Veloski, Ajay D. Rao, Ranee Mehra |
| المصدر: | Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-7 (2017) Journal for Immunotherapy of Cancer |
| بيانات النشر: | BMJ, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Adult, Insulin pump, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Diabetic ketoacidosis, Programmed Cell Death 1 Receptor, Immunology, non-small cell lung cancer (NSCLC), Antineoplastic Agents, Case Report, Non-small cell lung cancer (NSCLC), 030209 endocrinology & metabolism, Adenocarcinoma, lcsh:RC254-282, Diabetic Ketoacidosis, Autoimmune diabetes, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Diabetes mellitus, Diabetic ketoacidosis (DKA), medicine, Humans, Immunology and Allergy, Lung cancer, Pharmacology, Type 1 diabetes, business.industry, Autoantibody, Antibodies, Monoclonal, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, PD-1 inhibitor, Diabetes Mellitus, Type 1, Nivolumab, Immune related adverse events (irAE), 030220 oncology & carcinogenesis, Molecular Medicine, Female, business |
| الوصف: | Background Advances in cancer immunotherapy have generated encouraging results in multiple malignancies refractory to standard chemotherapies. As the use of immune checkpoint inhibitors (ICI) proliferates, the incidence of autoimmune side effects associated with these agents, termed immune related adverse events (irAE), is expected to increase. The frequency of significant irAE in ICI treated patients is about 10–20% and early recognition is critical to prevent serious morbidity and even mortality. New onset autoimmune diabetes mellitus (DM) associated with immune checkpoint inhibitor treatment is extremely rare, occurring in less than 1% of patients. Autoimmune DM often presents as diabetic ketoacidosis, a medical emergency requiring immediate treatment. We describe the first reported case of a patient with lung cancer who developed autoimmune diabetes after nivolumab treatment and was found to have three diabetes related (islet) autoantibodies present before ICI treatment and seroconversion of another after ICI treatment and onset of autoimmune DM. Case Presentation A 34 year old African American woman with metastatic non-small cell lung cancer (NSCLC) was treated with nivolumab in the second line setting after disease progression following standard chemoradiation therapy. After receiving two doses of nivolumab, the patient developed abrupt onset of hyperglycemia and diabetic ketoacidosis. Autoimmune diabetes was diagnosed on the basis of undetectable C-peptide levels, seropositivity of three diabetes related (islet) autoantibodies and absolute insulin dependence. The patient eventually required use of continuous subcutaneous insulin infusion (insulin pump) due to erratic glycemic excursions and multiple readmissions for DKA. Human leucocyte antigen (HLA) genoyping revealed none of the high risk haplotypes associated with the development of type 1 diabetes. Interestingly, a frozen blood sample obtained prior to treatment with nivolumab tested positive for three of the four diabetes related (islet) autoantibodies despite no prior history of diabetes and no family history of diabetes. Notably, at the time of manuscript preparation, the patient is without evidence of NSCLC recurrence with no further treatment since the nivolumab therapy. Conclusion New onset autoimmune diabetes mellitus associated with nivolumab has been described only in case reports and occurs at rates of |
| تدمد: | 2051-1426 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::459544cb137d0001088eed4725958af7Test https://doi.org/10.1186/s40425-017-0245-2Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....459544cb137d0001088eed4725958af7 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20511426 |
|---|